Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about ATTO, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| ATTO-1310 | Chronic Pruritus of Unknown Origin | Phase 2 · NCT07833306 | Not yet recruiting |
| ATTO-1091 | Ulcerative Colitis (UC) | Phase 1 · NCT07819799 | Not yet recruiting |
| ATTO-3712 | Normal Volunteers | Phase 1 · NCT07205081 | Completed |
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
ATTO holds $395.9M in cash and short-term investments (as of Sep 30, 2026) and burns about $20.4M/quarter from operations, an estimated runway of 58.2 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 0 · Low
Based on our current operating plan, we estimate that our existing cash, cash equivalents and marketable securities will be sufficient to fund our projected operating expenses and capital expenditure requirements into 2030.10-Q, Nov 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ATTO files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Frazier Life Sciences XI, L.P. 10% owner |
Insider | 6,154,213 | 13.46% | 2026-08-06 |
| venBio Global Strategic Fund IV, L.P. 10% owner |
Insider | 4,181,366 | 9.15% | 2026-09-30 |
| Alamar HoldCo, LLC 10% owner |
Insider | 3,229,278 | 7.06% | 2026-09-30 |
| Deep Track Capital, LP | Institution (13G, 5%+) | 3,207,138 | 7.02% | 2026-08-05 |
| GOLDMAN SACHS GROUP INC Former 10% Owner · +105,807 options |
Insider | 3,041,575 | 6.65% | 2026-09-30 |
| Colin Walsh Director · +105,807 options Includes shares also reported by GOLDMAN SACHS GROUP INC, counted once |
Insider | 3,020,632 | 6.61% | 2026-08-05 |
| Redmile Group, LLC 10% owner |
Insider | 2,165,708 | 4.74% | 2026-08-06 |
| Deep Track Biotechnology Master Fund, Lt 10% owner |
Insider | 1,957,138 | 4.28% | 2026-08-06 |
| Sanofi 10% owner |
Insider | 1,082,855 | 2.37% | 2026-08-06 |
| Tao Fu President and CEO, Director · +538,300 options |
Insider | 333,268 | 0.73% | 2026-08-04 |
| Attovia Therapeutics, Inc. Chief Financial Officer · +140,000 options Includes shares also reported by Tao Fu, counted once |
Insider | 333,268 | 0.73% | 2026-08-04 |
| Petter Veiby Chief Scientific Officer · +140,000 options |
Insider | 104,951 | 0.23% | 2026-08-04 |
Share count 45,712,536 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ATTO and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →